We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
James
Flanagan
j.flanagan@imperial.ac.uk
Dr
James
Flanagan
j.flanagan@imperial.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Malignant neoplasms of ill-defined, secondary and unspecified sites
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
An early cancer diagnosis is essential for receiving treatment as early as possible to have the best chance for successful treatment. Early diagnosis can be challenging for various forms of cancers such as colorectal, oesophageal, stomach, liver, bladder, uterine, vulval, ovarian, endometrial and pancreatic because their symptoms sometimes resemble common illnesses, and could resolve with the use of over the counter medications and other remedies until they become persistent or debilitating.
Patients diagnosed with the aforementioned cancers often report experiencing vague symptoms (such as body aches, indigestion, feeling full etc.) and used over-the-counter medication to manage their symptoms before seeing a doctor. We believe information about how often and what products participants purchase (e.g. pain killers, digestive products and natural remedies) to care for these symptoms could help identify these cancers a few crucial weeks or month earlier and promote people to seek help sooner from their doctors.
The Cancer Loyalty Card Study (CLOCS-2) is focused on improving early diagnosis of these cancer types. We are investigating whether or not your everyday loyalty card use in high street retailers can help identify early signs of cancers. CLOCS-2 aims to compare purchasing patterns of participants with (cases) and without (controls) cancer diagnoses to develop a way to potentially help diagnose cancer earlier. Early cancer diagnosis is vital for receiving treatment as early as possible to have the best chance for successful treatment. Early diagnosis can be challenging for various forms of cancers such as colon, oesophageal, stomach, liver, bladder, uterine, vulval, ovarian, endometrial and pancreatic because their symptoms sometimes resemble common illnesses, and could resolve with the use of over the counter medications and other remedies until they become persistent or debilitating.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Case-controlled study;
You can take part if:
You may not be able to take part if:
People under the age of 18 years and will not be eligible to join this study.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
James
Flanagan
j.flanagan@imperial.ac.uk
Dr
James
Flanagan
j.flanagan@imperial.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by CANCER RESEARCH UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 58679
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
